BioCentury | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

...than its current therapies, such as longer treatment duration for adults. Shire markets amphetamine drugs Adderall...
...see BioCentury, Jan. 18, 2016 ). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Neurology Elizabeth S. Eaton Adderall...
BioCentury | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

...than its current therapies, such as longer treatment duration for adults. Shire markets amphetamine drugs Adderall...
...added 44p to 3,708.50p in London and gained $1.69 to $150.79 in New York. Elizabeth S. Eaton Adderall...
BioCentury | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

...franchise revenues fell 3% to $635.4 million in 2Q17, primarily due to generic competition for Adderall...
BioCentury | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

...franchise revenues fell 3% to $635.4 million in 2Q17, primarily due to generic competition for Adderall...
BioCentury | May 23, 2016
Company News

Neos Therapeutics sales and marketing update

...which Shire plc (LSE:SHP; NASDAQ:SHPG, Dublin, Ireland) alleged that Neos’ NDA infringed Shire’s patents covering Adderall...
BioCentury | Feb 1, 2016
Clinical News

Adzenys XR-ODT amphetamine regulatory update

...Adzenys XR-ODT via the 505(b)(2) pathway after Neos demonstrated its bioequivalence to approved ADHD drug Adderall...
...settlement of a suit in which Shire alleged that Neos’ NDA infringed Shire’s patents covering Adderall...
BioCentury | Jan 29, 2016
Company News

Neos rises after ADHD approval

...Adzenys XR-ODT via the 505(b)(2) pathway after Neos demonstrated its bioequivalence to approved ADHD drug Adderall...
BioCentury | Sep 7, 2015
Clinical News

Amphetamine XR-ODT regulatory update

...suit in which Shire alleged that the NT-0202 NDA infringed Shire’s patents covering ADHD drug Adderall...
BioCentury | Nov 24, 2014
Company News

Shire pharmaceuticals news

...pay $2.9 million to resolve allegations over its sales, marketing and promotion of ADHD drugs Adderall...
BioCentury | Oct 20, 2014
Company News

Shire, Neos Therapeutics deal

...submitted to FDA for NT-0202 infringed Shire's U.S. Patent Nos. RE 42,096 and 41,148 covering Adderall...
...2019. Shire reported $375.4 million in 2013 sales of Adderall XR, an extended-release formulation of Adderall...
Items per page:
1 - 10 of 279